Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 12/20 | 0.50 |
| ▸ | HTR2A | P28223 | 10/20 | 0.50 |
| ▸ | HTR2C | P28335 | 10/20 | 0.50 |
| ▸ | HTR2B | P41595 | 10/20 | 0.50 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.49 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 10/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8674607 | 0.87 | CRBN (0.53) | SIGMAR1HTR2AHTR2CHTR2BADRA1D | |
| SCHEMBL6841626 | 0.87 | SIGMAR1 (0.68) | SIGMAR1HTR2AHTR2CHTR2BDRD2 | |
| SCHEMBL8916017 | 0.87 | HTR2A (0.52) | SIGMAR1HTR2AHTR2CHTR2BADRA1D | |
| SCHEMBL21856028 | 0.84 | LMNA (0.44) | SIGMAR1HTR2AHTR2CHTR2BADRA1D | |
| SCHEMBL25345704 | 0.83 | CYP3A4 (0.49) | SIGMAR1HTR2AHTR2CHTR2BADRA1D | |
| SCHEMBL25345710 | 0.81 | SIGMAR1 (0.47) | SIGMAR1HTR2AHTR2CHTR2BADRA1D | |
| SCHEMBL16407589 | 0.81 | LMNA (0.50) | SIGMAR1HTR2AHTR2CHTR2BADRA1D | |
| SCHEMBL27457057 | 0.81 | SIGMAR1 (0.73) | SIGMAR1HTR2AHTR2CHTR2BADRA1D | |
| SCHEMBL22770382 | 0.80 | ALDH1A1 (0.36) | SIGMAR1HTR2AHTR2CHTR2BADRA1D | |
| SCHEMBL21855747 | 0.80 | HTR2A (0.37) | SIGMAR1HTR2AHTR2CHTR2BDDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240124453-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2024-04-18 | — | — | US | disclosed |
| US-11884664-B2 | Protein tyrosine phosphatase inhibitors | ARRAY BIOPHARMA INC. (US) | 2024-01-30 | — | — | US | disclosed |
| EP-3867238-B1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-11634417-B2 | Protein tyrosine phosphatase inhibitors | ARRAY BIOPHARMA INC. (US) | 2023-04-25 | — | — | US | disclosed |
| US-20210380582-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2021-12-09 | — | — | US | disclosed |
| US-20200317665-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2020-10-08 | — | — | US | disclosed |
| WO-2020081848-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2020-04-23 | — | — | WO | disclosed |
| EP-0662481-B1 | Spiro piperidines and homologs promote release of growth hormone | MERCK & CO INC (US) | 1999-03-24 | — | — | EP | disclosed |
| US-5578593-A | RELEASING GROWTH HORMONES FOR ANIMALS | MERCK & CO., INC. (US) | 1996-11-26 | — | — | US | disclosed |
| EP-0662481-A1 | Spiro piperidines and homologs promote release of growth hormone | MERCK & CO. INC. (US) | 1995-07-12 | — | — | EP | disclosed |
| WO-1994019367-A1 | SPIRO PIPERIDINES AND HOMOLOGS PROMOTE RELEASE OF GROWTH HORMONE | MERCK & CO., INC. (US) | 1994-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11884664-B2 | Protein tyrosine phosphatase inhibitors | PPM1A, PPM1F, PPP5C | SIGMAR1 4337/4885HTR2A 4539/4885HTR2C 4335/4885 |
| US-20200317665-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | PPM1A, PPM1F, PPP5C | SIGMAR1 4337/4885HTR2A 4539/4885HTR2C 4335/4885 |
| US-20210380582-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | PPM1A, PTP4A1, PPP5C | SIGMAR1 4384/4885HTR2A 4423/4885HTR2C 4302/4885 |
| US-20240124453-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | PPM1A, PPM1F, PPP5C | SIGMAR1 4337/4885HTR2A 4539/4885HTR2C 4335/4885 |
| US-11634417-B2 | Protein tyrosine phosphatase inhibitors | PPM1A, PPM1F, PPP5C | SIGMAR1 4337/4885HTR2A 4539/4885HTR2C 4335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.